Allison is Associate Editorial Director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®. She joined AJMC® in 2017. She produces and oversees written, video, and podcast content across several disease states and issues surrounding value-based care and health policy.
She has an MPA from New York University. You can connect with Allison on LinkedIn.
Unmet Needs in Myasthenia Gravis Are Numerous, Says Dr James Howard
June 2nd 2023Unmet needs include both improved myasthenia gravis treatments as well as a way to monitor progression of the disease, said James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.
Read More
Dr Christopher Cannon on Dual SGLT1/2 Inhibitors
May 27th 2023Christopher P. Cannon, MD, a professor of medicine at Harvard Medical School and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital, spoke about the benefit seen in a study of sotagliflozin for patients with acute heart failure.
Read More
Step Therapy Requirements Are Worsening, Says Dr James Howard
May 19th 2023Myasthenia gravis expert James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the burdens that step therapy places on patients with rare diseases and their providers.
Read More
Communication, Teamwork Can Foster Resilience, Says Dr Lee Norman
May 14th 2023The best leaders are those who foster open communication, says Lee A. Norman, MD, MHS, MBA, who appeared at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event on population health in Kansas City, Missouri.
Read More
Deliberate Learning Can Help Providers Adapt, Says Dr Lee Norman
May 7th 2023Keeping up-to-date on information, whether it is about clinical matters or information systems, is critical to a deliberate learning mindset that is beneficial to health care providers, says Lee A. Norman, MD, MHS, MBA, the senior medical director for Optum Care Kansas City.
Read More
Dr Lee Norman on What to Consider in Value-Based Care Implementation
April 18th 2023Lee A. Norman, MD, MHS, MBA, who spoke at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event on population health March 9, 2023, in Kansas City, Missouri, discusses the shift to value-based care.
Read More
Antibiotics Do Not Cut Death Risk in Hospitalized Patients With Viral Respiratory Illnesses
March 24th 2023Although adults hospitalized with COVID-19, the flu, or respiratory syncytial virus are often administered antibiotics, the drugs have no effect on reducing the risk of death, according to a new study.
Read More
FDA Outlines Next Steps to Weave Digital Health Data Into Clinical Trials
March 24th 2023Digital health data can facilitate the participation of underrepresented and diverse patient populations in clinical trials, but first the FDA must build its capability to evaluate such information in its regulatory processes for new drug development.
Read More
Dangerous Drug-Resistant Yeast Infection Rising Across the US, CDC Says
March 20th 2023Candida auris was first reported in the United States in 2016; the highly contagious fungal infection has been labeled an “urgent threat” by the CDC, and its spread may have aided by underresourced public health systems.
Read More
Biden Administration Releases Drug Rebate List, Promotes End of Vaccine Cost Sharing
March 15th 2023The Biden administration released the list of 27 Medicare Part B drugs that are subject to rebates back to the government for having price increases that rose faster than inflation as well as the removal of out-of-pocket costs for some vaccines covered under Part D.
Read More
Dr Lee Norman on How the Pandemic Changed His Thoughts About Building Resilience
March 14th 2023Lee A. Norman, MD, MHS, MBA, spoke at The American Journal of Managed Care® (AJMC®)’s Institute for Value-Based Medicine®'s March 2023 event on population health about leading physician practices and navigating through change; here, he talks about how the COVID-19 pandemic shifted how he thinks about resiliency during times of intense stress and work.
Read More
42 Health Systems Picked for PCORI Plan to Move Clinical Research to Practice
March 3rd 2023Seeking to speed up the execution of evidence-based care practices, the Patient-Centered Outcomes Research Institute (PCORI) announced the 42 health systems across the country who will join a 5-year program to build capacity and implementation to improve health care outcomes.
Read More
FDA Approves Efanesoctocog Alfa for Hemophilia A
February 24th 2023Efanesoctocog alfa is the first factor VIII therapy to overcome the interaction with endogenous von Willebrand factor, which creates a ceiling of 8 to 19 hours on the half-life of current factor VIII replacement products, which in turn creates the need for more frequent dosing.
Read More
PD Worsens QOL, Increases Depression in Men More Than Women in the Southeast
February 17th 2023The southeastern areas of the country have worse health outcomes and health-related quality of life (HRQOL) compared with other parts of the United States, with high rates of diabetes, obesity, cancer, and cardiovascular disease.
Read More
CMS Outlines 3 New Drug Pricing Models Targeting Wide Scope of Therapies
February 14th 2023Targeting everyday chronic conditions to rare diseases that require costly, sometimes 1-time treatments, CMS Tuesday announced an intent to test 3 new models in an effort to lower drug prices and widen access to expensive, life-changing therapies for patients in Medicare and Medicaid.
Read More
CMS Releases Guidance on the Math Behind Part B, Part D Drug Rebates
February 10th 2023The Biden administration released 2 sets of guidance documents for pharmaceutical manufacturers about how it plans to implement the new Medicare Prescription Drug Inflation Rebate Program as required under the Inflation Reduction Act, and said some beneficiaries could see lower coinsurance for some Part B drugs as soon as April 1.
Read More
Brexucabtagene Autoleucel Shows High Rate of Durable Response at 3 Years
February 9th 2023Chimeric antigen receptor T-cell therapy brexucabtagene autoleucel showed a rate of complete remission of 71% and a rate of complete remission with incomplete hematologic recovery of 56%, according to 3-year follow-up results.
Read More